Literature DB >> 15352062

Extreme scale-down of expanded bed adsorption: Purification of an antibody fragment directly from recombinant E. coli culture.

Nik Willoughby1, Phillip Martin, Nigel Titchener-Hooker.   

Abstract

Scale-down is a methodology that combines the use of very small volumes of process fluid in dedicated devices to predict accurately the behaviour of process-scale biotechnological unit operations and for the production of comparable material for use in further devices which, taken together, facilitate the mimic of a complete full-scale process. This article provides the rationale behind the development of a small-scale mimic and demonstrates the use of a highly scaled-down expanded bed to predict hydrodynamic, kinetic, and adsorptive performance using less than 5-mL sample volumes. Data acquired on a specially developed 1.9 mm ID column was compared with that obtained in a standard 25 mm ID column. A homogenised E. coli system expressing an antibody fragment (F(ab)) adsorbed onto an rProtein A matrix was used to characterise the full adsorptive performance. Breakthrough curve studies using BSA in buffer were used to characterise binding kinetics. Performance at the two scales was comparable both in terms of expansion, axial dispersion, binding isotherms, and elution behaviour of the antibody fragment. The eluted F(ab) material was further purified by ion exchange chromatography to demonstrate the similarity between the profile of the product material obtained at both scales. The high level of scale-down (approximately 200-fold) provides for rapid process evaluation early in development, where material is at a premium and where a fast appreciation of the likely merits of one process strategy will lead to greater confidence in process selection and more robust flowsheets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352062     DOI: 10.1002/bit.20173

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  5 in total

1.  Purification of the therapeutic antibody trastuzumab from genetically modified plants using safflower Protein A-oleosin oilbody technology.

Authors:  Michael D McLean; Rongji Chen; Deqiang Yu; Kor-Zheng Mah; John Teat; Haifeng Wang; Steve Zaplachinski; Joseph Boothe; J Christopher Hall
Journal:  Transgenic Res       Date:  2012-03-02       Impact factor: 2.788

2.  Purification and Refolding of Overexpressed Human Basic Fibroblast Growth Factor in Escherichia coli.

Authors:  Mona Alibolandi; Hasan Mirzahoseini
Journal:  Biotechnol Res Int       Date:  2011-08-03

3.  IMAC capture of recombinant protein from unclarified mammalian cell feed streams.

Authors:  Alexander Kinna; Berend Tolner; Enrique Miranda Rota; Nigel Titchener-Hooker; Darren Nesbeth; Kerry Chester
Journal:  Biotechnol Bioeng       Date:  2015-09-03       Impact factor: 4.530

4.  An ultra scale-down method to investigate monoclonal antibody processing during tangential flow filtration using ultrafiltration membranes.

Authors:  Lara Fernandez-Cerezo; Andrea C M E Rayat; Alex Chatel; Jennifer M Pollard; Gary J Lye; Michael Hoare
Journal:  Biotechnol Bioeng       Date:  2019-01-04       Impact factor: 4.530

5.  In-Solution IgG Titer Determination in Fermentation Broth Using Affibodies and Flow-Induced Dispersion Analysis.

Authors:  Morten E Pedersen; Jesper Østergaard; Henrik Jensen
Journal:  ACS Omega       Date:  2020-04-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.